GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.
In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime. The company has invested in digital platforms and artificial intelligence tools designed to aggregate imaging and clinical data, support diagnostic decision-making and optimize operational performance. It also provides installation, maintenance, training and managed services to help hospitals and clinics manage capital assets and clinical operations across the equipment lifecycle.
GE HealthCare was previously the healthcare unit of General Electric and became an independent, publicly traded company in early 2023 following a corporate separation. The business has a long-standing presence in healthcare technology and continues to serve customers worldwide, including hospitals, outpatient centers, research institutions and specialty clinics across the Americas, Europe and the Asia-Pacific region. At the time of the separation, Kieran Murphy, who led the healthcare division within GE, continued as chief executive of the standalone company.
The company’s strategic focus emphasizes diagnostic excellence, digital transformation and service delivery to support value-based care initiatives. GE HealthCare positions its products and software to help clinicians accelerate diagnosis, improve patient throughput and reduce costs, while pursuing partnerships and R&D efforts to expand its clinical applications and global footprint.